Intangible assets (Details) $ in Millions |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Apr. 14, 2026
USD ($)
Program
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2025
USD ($)
|
|
| Intangible assets | ||||
| Purchase of intangible assets, classified as investing activities | $ 3,333 | $ 1,804 | ||
| Products in development | ||||
| Intangible assets | ||||
| Impairment loss recognised in profit or loss, intangible assets other than goodwill | $ 345 | |||
| Intangible assets from collaboration and license agreement with CSPC Pharmaceuticals | ||||
| Intangible assets | ||||
| Number of programmes initially progressed under collaboration agreement | Program | 4 | |||
| Purchase of intangible assets, classified as investing activities | 1,200 | |||
| Additions other than through business combinations, intangible assets other than goodwill | $ 1,100 | |||
| Maximum payables for regulatory milestones under collaboration agreement | $ 3,500 | |||